Sangamo Therapeutics
| Company type | Public |
|---|---|
| Nasdaq: SGMO Russell 2000 Index component | |
| Industry | Biotechnology |
| Founded | 1995 |
| Headquarters | Brisbane, California, US |
Key people | Sandy Macrae (CEO) Edward Rebar (CTO) |
| Revenue | $111.3 million (2022) |
| -$201.281 million (2022) | |
| $192.3 million (2022) | |
| Total assets | $562.5 million (2022) |
| Total equity | $294.958 million (2022) |
Number of employees | 354 |
| Website | sangamo |
| Footnotes / references | |
Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.